© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by click on this link.
Katie Adams –
Tuesday, October 27th, 2020
Eli Lillys antibody treatment bamlanivimab does not enhance healing times or survival rates for clients hospitalized with sophisticated COVID-19, the drugmaker said Oct. 26.
The drugmaker on Oct. 13 stopped briefly the scientific trial it is carrying out for the treatment with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The time out was set up after an independent security board discovered that, after 5 days of treatment, the group of clients who had actually received the antibodies showed a different “medical status” than the group who received the placebo, and the difference crossed a predetermined threshold for safety.
More articles on pharmacy: AstraZeneca, Johnson & & Johnson COVID-19 vaccine trials to resumeFloridas strategy to import cheaper drugs from Canada hits setbackBayer obtains gene treatment company for $4B.
The trial will not continue, but Eli Lilly stated other trials for the drug will go on to check its efficiency for clients who have not been exposed to COVID-19 or have milder cases of the disease.
” While there was insufficient evidence that bamlanivimab improved clinical outcomes when contributed to other treatments in hospitalized patients with COVID-19, we stay confident based upon data from Lillys BLAZE-1 study that bamlanivimab monotherapy may prevent progression of illness for those earlier in the course of COVID-19,” the drugmaker said in a press release.